SECURITIES AND EXCHANGE COMMISSION
     Washington, D.C.


     Litigation Release No. 15786  / June 18, 1998

     Accounting and Auditing Enforcement
     Release No.  1046 / June 18, 1998

     SEC v. William P. Trainor, Vincent D. Celentano, Medical Diagnostic
     Products, Inc. (f/k/a Novatek International, Inc.), Karen Losordo, Diane M.
     Trainor, Daniel J. Trainor, Geraldine Trainor and Mary N. Celentano  (Civil
     Action No. 98-CV01533) (EGS) (USDC/DC)

     The Commission today filed a Complaint in the United States District Court
     for the District of Columbia against Medical Diagnostic Products, Inc.
     (f/k/a Novatek International, Inc.  Novatek  ), a Columbia Maryland-based
     company that purports to distribute medical diagnostic test kits, William
     P. Trainor and Vincent D. Celentano.  The Commission s Complaint alleges
     that Trainor and Celentano committed a massive fraud on investors by, among
     other things, orchestrating a series of sham transactions among Novatek and
     other companies that they controlled, followed by their issuing a series of
     press releases which announced that Novatek had entered into highly
     profitable contracts with a variety of other entities.  No such contracts
     existed. The Complaint also names Karen Losordo, Diane M. Trainor, Daniel
     J. Trainor, Geraldine Trainor and Mary N. Celentano as relief defendants.

     The Complaint alleges that the defendants violated the antifraud and
     reporting provisions of the Securities Exchange Act of 1934, specifically
     Sections 10(b), 13(a), 13(b)(2)(A) and (B), 13(b)(5), 13(d) and 16(a) and
     Rules 10b-5, 12b-20, 13a-13, 13b2-1, 13d-1 and 16a-3 thereunder, and seeks
     to enjoin them from future violations of the federal securities laws.  The
     Complaint also seeks to obtain civil penalties from the individual
     defendants and to bar them from serving as officers or directors of public
     companies.

      The Complaint further alleges that Trainor and Celentano controlled
     Novatek, although neither they nor the company disclosed this fact to
     investors.  Through the sham transactions, the last of which occurred in
     April 1996 and involved a merger between Novatek and Medical Products, Inc.
     ( MPI ), a private company owned by Trainor and Celentano, Novatek acquired
     a license to distribute medical diagnostic test kits in South America and
     Latin America.  Novatek accounted for the combination on its financial
     statements as an acquisition of MPI by Novatek and falsely claimed that the
     distribution license had a value in excess of $50 million.  From that point
     until October 1996, Trainor and Celentano caused the price of Novatek
     common stock to increase by knowingly or recklessly causing Novatek to
     issue materially false and misleading press releases which falsely  stated,
     among other things, that Novatek had entered into agreements worth a total
     of $400 million with various South American and Latin American entities. 
     The Complaint also alleges that Trainor and Celentano fraudulently
     disbursed more than $4.5 million of Novatek investor funds to family

                              ======END OF PAGE 1======





     members and entities associated with them without any legitimate business
     reason.

     The Complaint further alleges that Trainor and Celentano caused Novatek to
     file periodic reports with the Commission on Forms 8-K/A and 10-QSB that
     contained materially false and misleading financial statements.  Novatek
     grossly overstated the value of its assets at more than $57 million when,
     in reality, Novatek s assets were approximately $2 million.

       The Commission acknowledges the assistance of the National Association of
     Securities Dealers, the Comissƒo De Valores Mobiliarios of Brazil, the
     Comision Nacional De Valores de Argentina, and the Superintendencia De
     Valores y Seguros of Chile  in this matter.











































                              ======END OF PAGE 2======